-
Site License
-
Site License
-
Enterprisewide
-
Enterprisewide
Life Sciences Funding in Europe (2007)
Frost & Sullivan, March 2008, Pages: 88
This Frost & Sullivan research service titled Life Sciences Funding in Europe (2007) provides an overview of funding challenges, initiatives taken to overcome them and key policies implemented, including developments in the framework programme funded by the European Commission. Funding volumes of various public, private and charity organisations in the major EU nations and their impact on the R&D quality have been analysed. In this research, Frost & Sullivan's expert analysts thoroughly examine life sciences research markets in the United Kingdom, Germany, France, Italy and Spain.
Market Overview
Support from the European Commission and Countries Strong in Life Sciences Research Provide Fillip to Funding Inflows
Funding for research in life sciences across Europe has been gaining importance in recent years. However, the productivity of life sciences research in Europe still lags behind the United States, with comprehensive measures having been implemented to improve the quality of Europe’s research base. The lack of funding for late-stage development and commercialisation has been responsible for the limited productivity in the small and medium enterprise (SME) sectors. With the industry’s focus shifting towards biological drugs, Europe is according top priority to investing in R&D. However, major pharmaceutical and biotech companies continue to shift their R&D base to the United States. This trend has slowed down the development of life sciences research in Europe. Weak tax incentive schemes for private investment in R&D companies have been identified as the main reason for several companies preferring to base their operations in the United States. Accordingly, tax incentives in major EU nations are being revised to encourage R&D.
"European life sciences funding is rising at a healthy pace, driven mainly by the commitment of the European Commission and research-performing nations to boost R&D productivity," notes the analyst of this research. "In addition to the support from major EU nations, these positive trends are being buttressed by the framework programmes for financing R&D in universities and SMEs". The European Commission has started the seventh Framework Programme (FP7), which offers increased funding and wider objectives. FP7 is the next step in realising the objectives set in the Lisbon strategy. It provides funding for life sciences through the ‘Health theme’, which aims at increasing Europe’s competitiveness. At the same time, the establishment of ERC offers enhanced support for basic research in life sciences. The European Commission has promised to augment the financial support for SMEs in the life sciences industry.
Lack of Cohesion Looms as a Major Threat to Market Development
The European funding landscape is highly fragmented. While several public, private and charity bodies contribute to funding research, the goals and objectives vary among organisations, making it difficult to maximise on results. "With varying policies across Europe, there is a risk of replication and hence, a wastage of money and effort," explains the analyst of this research. "At the moment, there is not enough communication across the EU to promote a coordinated effort towards achieving research goals."
Moreover, EU-backed initiatives cover projects that are too large to manage and coordinate among the large number of participating countries. Europe needs to streamline its research policies and goals to optimise on the output of R&D in life sciences. Funding made available for SMEs and other individual projects have to be enhanced in size to support late-stage development phases.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following geographic areas in this research:
- United Kingdom
- Germany
- France
- Italy
- Spain
1. Executive Summary
- 1. Overview of the Life Sciences Funding in Europe
- - 1. Executive Summary of the Life Sciences Funding in Europe
2. Glossary
- 1. Glossary of Terms
- - 1. Terminologies
- 2. Key Acronyms
- - 1. Acronyms
3. Assumptions and Methodology
- 1. Research Scope and Methodology
- - 1. Research Scope and Segmentation
4. Funding in Europe
- 1. Funding Landscape
- - 1. Funding Scenario
- 2. European Funding Overview
- - 1. European Funding Challenges
- - 2. Market Engineering Measurements
- - 3. Funding Analysis
5. Funding in the United Kingdom
- 1. Funding Overview
- - 1. Overview
- 2. Market Engineering Measurements
- - 1. Market Engineering Research
- 3. Funding Scenario
- - 1. Funding Analysis
6. Funding in Germany
- 1. Funding Overview
- - 1. Overview
- 2. Market Engineering Measurements
- - 1. Market Engineering Research
- 3. Funding Scenario
- - 1. Funding Analysis
7. Funding in France
- 1. Funding Overview
- - 1. Overview
- 2. Market Engineering Measurements
- - 1. Market Engineering Research
- 3. Funding Scenario
- - 1. Funding Analysis
8. Funding in Italy
- 1. Funding Overview
- - 1. Overview
- 2. Market Engineering Measurements
- - 1. Market Engineering Research
- 3. Funding Scenario
- - 1. Funding Analysis
9. Funding in Spain
- 1. Funding Overview
- - 1. Overview
- 2. Market Engineering Measurements
- - 1. Market Engineering Research
- 3. Funding Scenario
- - 1. Funding Analysis
10. Decision Support Database
- 1. Database Tables
- - 1. Biotech Companies
- - 2. Biotech Private Investment
- - 3. Per cent of Government Investment in Biotechnology
- - 4. Government Biotech R&D Investment
- - 5. Enrollment of Students
List of Figures
Chapter 4
- Life Sciences Funding 2007: Overview of Thematic Priorities Covered Under FP7 (Europe), 2006
- Life Sciences Funding 2007: Funding Challenges (Europe), 2007-2010
- Life Sciences Funding 2007: Topics Excluded from FP7 Funding Under the Health Theme (Europe), 2006
- Life Sciences Funding 2007: Comparison of Life Sciences Scenario between Europe and the United States (Europe), 2004
- Life Sciences Funding 2007: Estimated Construction Costs for Infrastructure Proposed by ESFRI in the Area of Biomedical and Life Sciences Research (Europe), 2007-2010
Chapter 5
- Life Sciences Funding 2007: Revenue Forecasts (The United Kingdom), 2006-2010
- Life Sciences Funding 2007: Funding Projections of Major Research Councils (The United Kingdom), 2006-2010
- Life Sciences Funding 2007: BBSRC Funding Projection by Research Area (The United Kingdom), 2007-2010
- Life Sciences Funding 2007: Charity Funding Forecasts for Life Sciences Research (The United Kingdom), 2006-2009
Chapter 6
- Life Sciences Funding 2007: Revenue Forecasts (Germany), 2006-2010
Chapter 7
- Life Sciences Funding 2007: Revenue Forecasts (France), 2006-2010
Chapter 8
- Life Sciences Funding 2007: Revenue Forecasts (Italy), 2006-2010
Chapter 9
- Life Sciences Funding 2007: Revenue Forecasts (Spain), 2006-2010
Chapter 10
- Decision Support Database: Number of Biotech Companies (World), 2002-2012
- Decision Support Database: Venture Capital Investment in Biotech R&D in Million USD (World), 2002-2012
- Decision Support Database: Per cent of Government Biotech R&D Investment (World), 2002-2012
- Decision Support Database: Government R&D Expenditure in Biotechnology in Million USD (World), 2002-2012
- Decision Support Database: Total Number of Students Doing Graduation and Postgraduation in '000 (World), 2002-2012
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
